New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
08:12 EDTHSP, DANOYHospira to obtain financial benefits from possible Danone deal, says Wells Fargo
After multiple media sources reported that Hospira (HSP) is in talks to buy Danone's (DANOY) medical nutrition business in a potential tax inversion deal, Wells Fargo estimates that the deal could be 9%-12% accretive to Hospira's EPS in 2015-2017 if it's an all-stock deal and 20%-22% accretive if it's a 50%/50% cash and stock deal. The firm The firm estimates that Hospira's tax bill would be cut to 21% in 2015 and 19% afterwards, from its current forecast of 24%-26% during those years. The firm thinks the strategic rationale for the deal from Hospira's perspective, however, is less clear. It keeps a Market Perform rating on the stock.
News For HSP;DANOY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
09:41 EDTHSPHospira launches generic Remicade, WSJ says
Subscribe for More Information
February 20, 2015
06:25 EDTDANOYDanone board to ask shareholders to approve increased dividend of EUR1.50
Subscribe for More Information
06:24 EDTDANOYDanone targets 2015 organic growth in sales of between 4%-5%
Danone assumes that economic conditions will remain difficult and unstable overall, with fragile or even deflationary consumer trends in Europe, emerging markets undermined by volatile currencies, and difficulties specific to a few major markets, in particular the CIS. In 2015, Danone also anticipates marked but varied trends in the cost of major strategic raw materials, particularly milk; lower prices in Europe and the United States in the first half, with a rebound likely in the second half of the year, and gradual price increases in emerging countries all year long. Altogether, Danone anticipates a moderate rise in the cost of main raw materials and packaging in 2015. Sees slight growth in trading operating margin in 2015.
06:22 EDTDANOYDanone reports FY14 EPS EUR2.62
Subscribe for More Information
06:18 EDTDANOYDanone warns of volatility in years ahead, sees 'difficult' conditions in 2015
Subscribe for More Information
February 19, 2015
06:17 EDTHSPHospira Inflectra patient registry reports interim results in treatment of IBD
Data have been presented on the use of Hospira's Inflectra, the world's first approved biosimilar monoclonal antibody, or mAb, at the European Crohn's and Colitis Organisation Inflammatory Bowel Diseases, or ECCO-ibd, conference. Results show a comparable response in patients treated with Inflectra to that expected with the reference product, Remicade, for inducing and maintaining remission in Crohn's disease, or CD, and ulcerative colitis, or UC. These data add to the body of evidence supporting Inflectra's use in inflammatory bowel disease, or IBD. Results presented from the ongoing independent, prospective, nationwide study in Hungary show that for the first 90 patients, treated with Inflectra, reductions compared with baseline were seen in validated measures of disease activity after both two and six weeks of treatment. C-reactive protein, or CRP, a marker of inflammation, was also decreased during induction therapy for UC. Four of the 90 patients showed an allergic reaction to treatment, all of who had previously received anti-TNF medication. The abstract can be found at: P314 Biosimilar infliximab in inflammatory bowel diseases: first interim results from a prospective nationwide observational cohort.
February 18, 2015
10:05 EDTDANOYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Agnico Eagle (AEM) upgraded to Overweight from Neutral at JPMorgan... Amarin (AMRN) upgraded to Buy from Neutral at SunTrust... Capital Product (CPLP) upgraded to Accumulate from Neutral at Global Hunter... Carlyle Group (CG) upgraded to Buy from Neutral at Citigroup... Danone (DANOY) upgraded to Neutral from Underperform at Exane BNP Paribas... Express (EXPR) upgraded on lower promotional activity at Piper Jaffray... Kforce (KFRC) upgraded to Outperform from Market Perform at Avondale... Legg Mason (LM) upgraded to Buy from Hold at Jefferies... Rackspace (RAX) upgraded following Q4 results at Pacific Crest... Rosetta Resources (ROSE) upgraded to Buy from Neutral at Global Hunter... SeaChange (SEAC) upgraded to Buy from Hold at Noble Financial... Valero (VLO) upgraded to Outperform from Neutral at Credit Suisse... Veeco (VECO) upgraded to Buy from Hold at Noble Financial... Wolverine World Wide (WWW) upgraded to Neutral from Underperform at Sterne Agee.
08:41 EDTHSPThe Medicines Co. says not giving financial guidance due to Hospira suit
Subscribe for More Information
06:01 EDTDANOYDanone upgraded to Neutral from Underperform at Exane BNP Paribas
Subscribe for More Information
February 17, 2015
04:47 EDTHSPPfenex price target raised to $16 from $12 at Mizuho
Subscribe for More Information
February 12, 2015
15:12 EDTHSPJ&J Remicade appeal process could take years to resolve, says Wells Fargo
Subscribe for More Information
10:49 EDTHSPWellington Management reports 6.62% passive stake in Hospira
07:33 EDTHSPHospira not announcing FY15 projections due to recent merger argreement
Subscribe for More Information
07:32 EDTHSPHospira reports Q4 adjusted EPS 53c, consensus 42c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use